Adagene

A proprietary antibody engineering platform sits at the core of Adagene, a Nasdaq-listed, clinical-stage immunotherapy company working to redefine how antibodies are discovered and designed for cancer treatment. Operating globally, the company has built its approach around the Dynamic Precision Library, a computational and structural biology platform that generates antibody candidates with enhanced precision and therapeutic potential.

Three distinct antibody modalities underpin the platform. NEObody candidates are designed to access previously undruggable epitopes; SAFEbody molecules incorporate a masking mechanism intended to improve the therapeutic window; and POWERbody formats are engineered for potentiated immune engagement. Together, these technologies give Adagene a differentiated toolkit for addressing difficult oncology targets.

The company's clinical pipeline includes ADG126, ADG116, ADG206 and ADG106, each progressing through clinical evaluation as part of a broader portfolio that also encompasses preclinical programmes. Adagene pursues its development objectives both independently and through external collaborations, reflecting a partnered model that extends the reach of its platform across the industry.

As a public company listed on Nasdaq, Adagene operates under the governance and disclosure standards associated with that market, with oversight from a board of directors and a scientific and strategic advisory board. The organisation's commitment to antibody innovation positions it within the competitive immuno-oncology space, where platform differentiation and clinical progress are the key measures of progress.

Further information is available at adagene.com.